{"id":"latanoprost-punctal-plug-delivery-system","safety":{"commonSideEffects":[{"rate":"null","effect":"Conjunctival hyperemia"},{"rate":"null","effect":"Eye irritation"}]},"_chembl":{"chemblId":"CHEMBL1051","moleculeType":"Small molecule","molecularWeight":"432.60"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved by using a punctal plug to release latanoprost, which then acts on the eye's trabecular meshwork to increase aqueous humor outflow and decrease intraocular pressure. This is particularly useful for patients with glaucoma or ocular hypertension.","oneSentence":"Latanoprost Punctal Plug Delivery System works by delivering latanoprost, a prostaglandin F2α analogue, directly to the eye to reduce intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:41:37.438Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of glaucoma and ocular hypertension"}]},"trialDetails":[{"nctId":"NCT02014142","phase":"PHASE2","title":"A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Mati Therapeutics Inc.","startDate":"2013-12","conditions":"Ocular Hypertension, Open-Angle Glaucoma","enrollment":86},{"nctId":"NCT01037036","phase":"PHASE2","title":"A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG","status":"COMPLETED","sponsor":"Mati Therapeutics Inc.","startDate":"2009-12","conditions":"Ocular Hypertension, Open-Angle Glaucoma","enrollment":15},{"nctId":"NCT01481077","phase":"PHASE2","title":"A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Mati Therapeutics Inc.","startDate":"2011-11","conditions":"Glaucoma, Ocular Hypertension (OH)","enrollment":77},{"nctId":"NCT01481051","phase":"PHASE2","title":"A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Mati Therapeutics Inc.","startDate":"2011-11","conditions":"Glaucoma, Ocular Hypertension (OH)","enrollment":57},{"nctId":"NCT00845299","phase":"PHASE2","title":"Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Mati Therapeutics Inc.","startDate":"2009-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":40},{"nctId":"NCT00820300","phase":"PHASE2","title":"A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma","status":"COMPLETED","sponsor":"Mati Therapeutics Inc.","startDate":"2009-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":113},{"nctId":"NCT00821002","phase":"PHASE2","title":"A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)","status":"COMPLETED","sponsor":"Mati Therapeutics Inc.","startDate":"2009-01","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":32},{"nctId":"NCT01229982","phase":"PHASE2","title":"A Study Evaluating the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Mati Therapeutics Inc.","startDate":"2010-10","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":121},{"nctId":"NCT00967811","phase":"PHASE2","title":"A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG","status":"COMPLETED","sponsor":"Mati Therapeutics Inc.","startDate":"2009-08","conditions":"Glaucoma, Ocular Hypertension","enrollment":83},{"nctId":"NCT00855517","phase":"PHASE2","title":"A Phase 2 Study of the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma","status":"WITHDRAWN","sponsor":"Mati Therapeutics Inc.","startDate":"2009-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Latanoprost Punctal Plug Delivery System","genericName":"Latanoprost Punctal Plug Delivery System","companyName":"Mati Therapeutics Inc.","companyId":"mati-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Latanoprost Punctal Plug Delivery System works by delivering latanoprost, a prostaglandin F2α analogue, directly to the eye to reduce intraocular pressure. Used for Treatment of glaucoma and ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}